pb-22 pb-22 pb-22 (qupic, sgt-21 or 1-pentyl-1h-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in japan in 2013. pb-22 represents a structurally unique synthetic cannabinoid chemotype, since it contains an ester linker at the indole 3-position, rather than the precedented ketone of jwh-018 and its analogs, or the amide of apica and its analogs. pb-22legal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) uk: class b us: schedule i identifiers iupac name 1-pentyl-1h-indole-3-carboxylic acid 8-quinolinyl ester cas number1400742-17-7chemspider29339966uniiqm6j8f29fecomptox dashboard (epa)dtxsid70856177 echa infocard100.233.114 chemical and physical dataformulac23h22n2o2molar mass358.441 g·mol−13d model (jsmol)interactive image smiles cccccn1c=c(c2=cc=cc=c21)c(=o)oc3=cc=cc4=c3n=cc=c4 inchi inchi=1s/c23h22n2o2/c1-2-3-6-15-25-16-19(18-11-4-5-12-20(18)25)23(26)27-21-13-7-9-17-10-8-14-24-22(17)21/h4-5,7-14,16h,2-3,6,15h2,1h3key:zavgicceaouwfm-uhfffaoysa-n pb-22 has an ec50 of 5.1 nm for human cb1 receptors, and 37 nm for human cb2 receptors. pb-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. the magnitude and duration of hypothermia induced in rats by pb-22 was notably greater than jwh-018, am-2201, ur-144, xlr-11, apica, or sts-135, with a reduction of body temperature still observable six hours after dosing. one clinical toxicology study found pb-22 to be the cause of seizures in a human and his dog. history pb-22 was originally developed by new zealand legal highs company stargate international in 2012 as sgt-21, intended to be a structural hybrid of qmpsb and jwh-018. however, no intellectual property protection was applied for and the compound quickly became subject to widespread grey-market sales outside the control of the inventors. detection a forensic standard of pb-22 is available, and the compound has been posted on the forendex website of potential drugs of abuse. legal status as of 9 may 2014, pb-22 is no longer legal in new zealand. in january 2014, pb-22 was designated as a schedule i controlled substance in the united states. in ohio, pb-22 is illegal. florida also has banned pb-22. since 13 december 2014 it is also illegal in germany because of adding the substance to the btmg anlage ii. as of october 2015 pb-22 is a controlled substance in china.